USBiomarkers, Inc

Mature platform technology for diagnostic, predictive, and prognostic tests in blood. Blood-based companion diagnostics and monitoring.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Buffalo Grove, IL, USA
  • Currency USD
  • Founded February 2010
  • Employees 3
  • Website USBiomarkers.com

Company Summary

USB develops and intends to market biomarkers and blood-based diagnostic (Dx) tests for cancer and neurodegenerative diseases (e.g. multiple sclerosis). The Dx market grows due to aging populations, and healthcare costs. Matching of drugs to patients (companion Dx) and patient monitoring (personalized medicine) require tests. Customers are individuals, pharma and molecular Dx companies, and medical groups.

Team

  • Victor Levenson
    President, CSO and interim CEO

    Dr. Levenson, MD (2nd Moscow State Medical School, 1981), and PhD (Molecular and Cellular Biology, Institute of Molecular Biology, Moscow, USSR, 1985) held faculty positions, received multiple awards from national foundations and NIH, published over 45 peer-reviewed articles, reviews. He acts as the interim CEO. His experience with project design for test/biomarker development is instrumental for USB success.

  • Anatoliy Melnikov
    CTO

    Dr. Melnikov, PhD (Genetic Engineering, Puschino, USSR, 1983) is a biochemist and enzymologist, who co-developed the MethDet technology for routine clinical analysis. He was a Sr. Group Leader at Integrated Genomics, Inc, a biotechnology company before joining with Dr. Levenson. He authored over 30 peer-reviewed publications and continues development of the assay to make it faster, cheaper, more accurate, and easier to perform.

  • Sergei Bavykin
    COO

    Dr. Bavykin, MD (1975), PhD, and DSc (1980 and 1992) held faculty positions and authored more than 40 peer-reviewed papers, 7 patents and more than thirty software programs. He is an expert in microarray technology, bioassay development, and bioinformatics. He is responsible for bioinformatics analysis of data for high-resolution genome-wide development of tests/biomarkers.

Advisors

  • Brian Cyr
    Lawyer
    Unconfirmed
    Brad Filmanowitz
    Accountant
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free